Heron Therapeutics, Inc.

NasdaqCM:HRTX Stock Report

Market Cap: US$240.3m

Heron Therapeutics Future Growth

Future criteria checks 4/6

Heron Therapeutics is forecast to grow earnings and revenue by 71.2% and 13.8% per annum respectively while EPS is expected to grow by 71.1% per annum.

Key information

71.2%

Earnings growth rate

71.1%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate13.8%
Future return on equityn/a
Analyst coverage

Low

Last updated04 Dec 2024

Recent future growth updates

Recent updates

Why Investors Shouldn't Be Surprised By Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 30% Share Price Plunge

Nov 13
Why Investors Shouldn't Be Surprised By Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 30% Share Price Plunge

Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 30%

Nov 13
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 30%

Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%

Aug 08
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

May 30
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain

Apr 16

Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results

Mar 15
Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results

Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Feb 15
Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%

Dec 22
Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%

Heron wins FDA nod for post-operative agent to address nausea and vomiting

Sep 16

Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?

Aug 10
Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?

Heron Therapeutics Q2 2022 Earnings Preview

Aug 08

Heron Therapeutics proposes 34% cut in workforce as part of cost reduction plan

Jun 30

Heron Therapeutics: Cash Is A Problem Again

Mar 31

Heron Therapeutics: Changing Strategy After Disappointing Earnings

Mar 03

Health Check: How Prudently Does Heron Therapeutics (NASDAQ:HRTX) Use Debt?

Jan 19
Health Check: How Prudently Does Heron Therapeutics (NASDAQ:HRTX) Use Debt?

Heron Therapeutics: Looking For Signs Of The Bottom

Oct 07

Is Heron Therapeutics (NASDAQ:HRTX) Using Too Much Debt?

Oct 03
Is Heron Therapeutics (NASDAQ:HRTX) Using Too Much Debt?

Earnings and Revenue Growth Forecasts

NasdaqCM:HRTX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261902031N/A2
12/31/2025167-513N/A3
12/31/2024141-180N/A3
9/30/2024138-28-10-8N/A
6/30/2024136-48-23-21N/A
3/31/2024132-81-45-43N/A
12/31/2023127-111-60-59N/A
9/30/2023123-120-100-99N/A
6/30/2023118-137-128-127N/A
3/31/2023114-151-129-128N/A
12/31/2022108-182-149-147N/A
9/30/202298-217-156-155N/A
6/30/202295-227-174-171N/A
3/31/202290-232-209-205N/A
12/31/202186-221-206-203N/A
9/30/202186-228-216-211N/A
6/30/202183-234-204-200N/A
3/31/202183-228-198-194N/A
12/31/202089-227-192-185N/A
9/30/2020103-223-167-159N/A
6/30/2020126-198-149-143N/A
3/31/2020140-193-116-108N/A
12/31/2019146-205-132-125N/A
9/30/2019140-196-138-131N/A
6/30/2019117-201-153-141N/A
3/31/201998-190-190-179N/A
12/31/201877-179-201-192N/A
9/30/201859-192-212-205N/A
6/30/201847-195N/A-210N/A
3/31/201839-199N/A-181N/A
12/31/201731-197N/A-170N/A
9/30/201722-183N/A-162N/A
6/30/201713-190N/A-157N/A
3/31/20175-190N/A-152N/A
12/31/20161-173N/A-134N/A
9/30/2016N/A-156N/A-119N/A
6/30/2016N/A-131N/A-102N/A
3/31/2016N/A-110N/A-91N/A
12/31/2015N/A-98N/A-79N/A
9/30/2015N/A-87N/A-68N/A
6/30/2015N/A-83N/A-68N/A
3/31/2015N/A-79N/A-64N/A
12/31/2014N/A-76N/A-60N/A
9/30/2014N/A-70N/A-57N/A
6/30/2014N/A-63N/A-50N/A
3/31/2014N/A-60N/A-49N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HRTX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: HRTX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: HRTX is expected to become profitable in the next 3 years.

Revenue vs Market: HRTX's revenue (13.8% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: HRTX's revenue (13.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if HRTX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 10:07
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Heron Therapeutics, Inc. is covered by 21 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Boran WangAegis Capital Corporation
Tazeen AhmadBofA Global Research
Jonathan AschoffBrean Capital